Target
NY-ESO-1
2 products, 2 indications
Indications
Advanced solid tumors (ovarian, prostate, breast cancer) (1 products)
Metastatic Castration-Resistant Prostate Cancer (1 products)
Loading...
1 drug
3 abstracts
Abstract
Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.Org: Memorial Sloan Kettering Cancer Center, Royal Marsden NHS Foundation Trust, The Christie NHS Foundation Trust and University of Manchester, University of Pittsburgh Medical Center (UPMC), Duke Cancer Institute,
Abstract
Results from phase I/II study of NY-ESO-1-specific TCR gene-transduced T cell therapy (TBI-1301, mipetresgene autoleucel) in patients with advanced synovial sarcoma.Org: National Cancer Center Hospital East, Kashiwa, Japan, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Mie University Hospital, Tsu, Japan, Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto-Shi, Japan, Mie University Graduate School of Medicine, Tsu, Japan,
Abstract
Next generation sequencing reveals targetable mutations in multiple sarcoma histologies.Org: Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Vander Ingram Cancer Center, Division of Epidemiology and Community Health,
Drug
OVV-01